GlassScriptPhysician profile
Mollie Cartwright
NPI 1679669451
$1,660.42
in general payments reported to CMS, 2019-2025
26 companies · $200 in 2025
The $200 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.28 · 2021: $159 · 2022: $830 · 2023: $252 · 2024: $131 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $582.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $320.64 | 2022-2023 | Ova1 |
| Abbvie INC. | $252.64 | 2019-2023 | Orilissa, Lo Loestrin Fe |
| Astellas Pharma Global Development | $150.10 | 2025 | Veozah |
| Exeltis, USA INC. | $120.66 | 2022-2025 | Slynd |
| Myovant Sciences INC. | $109.00 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $99.66 | 2022-2023 | |
| Hologic Sales and Service, LLC | $74.11 | 2022-2025 | Aptima, Acessa Provu System, Novasure |
| Avion Pharmaceuticals | $61.54 | 2021-2022 | |
| Agile Therapeutics, INC. | $56.17 | 2022 | |
| Therapeuticsmd, INC. | $47.34 | 2022 | |
| Lupin INC. | $42.91 | 2019 | |
| Astellas Pharma US INC | $42.46 | 2021-2024 | Veozah |
| Organon LLC | $36.73 | 2021-2024 | |
| Channel Medsystems, INC. | $36.34 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.93 | 2019-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $27.35 | 2022 | |
| Daiichi Sankyo INC. | $18.99 | 2025 | Injectafer |
| Sumitomo Pharma America, INC. | $17.88 | 2023 | Myfembree |
| Virtus Pharmaceuticals LLC | $17.69 | 2021 | |
| Evofem Biosciences, INC. | $16.69 | 2022 | |
| Pharmacosmos Therapeutics INC. | $15.28 | 2023 | Monoferric |
| Mylan Pharmaceuticals INC. | $14.71 | 2022 | |
| Coopersurgical, INC. | $13.71 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.51 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $13.08 | 2022 | |
| Amgen INC. | $11.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mollie Cartwright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.